Investing.com -- Shares of Axsome Therapeutics Inc (NASDAQ: AXSM) fell 1.2% following the U.S. Food and Drug Administration’s (FDA) Refusal to File (RTF) letter regarding the company’s New Drug ...

Axsome Therapeutics (AXSM) shares drop after FDA declines review of fibromyalgia treatment AXS-14. Read more here.

Shares of Axsome Therapeutics, Inc. (AXSM) slumped 3% in the pre-market session on Monday after the company said that it has ...

Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced ...

Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, and Taiwan-based Formosa Pharmaceuticals ('Formosa', 6838.TW), today announced a licensing agreement, whereby Harrow has ...

Bitcoin’s success reflects a growing shift in how the world approaches not only cryptocurrency but also financial markets as ...

Axsome Therapeutics received a refusal-to-file letter from the Food and Drug Administration for its new drug application for its fibromyalgia drug AXS-14.

Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today ...

Speaking at the official opening of the Seventh Annual General Meeting of the Tanzania Teachers’ Union (CWT) in Dodoma ...

How Rick Carter, producer designer of blockbusters for Steven Spielberg and Jim Cameron, sees GenAI emerging as a ...

RBI's big beautiful monetary policy, rising market activity a cause for concern, global growth slows but markets are soaring, ...

Vineeth Gogineni is a Manager at Bain & Company, based in the Dallas office, serving private and public sector clients across ...